A Randomized, Phase 2a, Partially-Blind, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naive Subjects With Chronic Hepatitis C

Trial Profile

A Randomized, Phase 2a, Partially-Blind, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naive Subjects With Chronic Hepatitis C

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Jul 2014

At a glance

  • Drugs VX 135 (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Sponsors Alios BioPharma
  • Most Recent Events

    • 30 Oct 2013 Results were reported in a Vertex Pharmaceuticals media release.
    • 30 Oct 2013 Status changed from active, no longer recruiting to completed, as reported in a Vertex Pharmaceuticals media release.
    • 30 Jul 2013 According to a Vertex media release, dosing has been completed in this trial. Results are anticipated later this year.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top